<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762928</url>
  </required_header>
  <id_info>
    <org_study_id>B7981017</org_study_id>
    <nct_id>NCT03762928</nct_id>
  </id_info>
  <brief_title>ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will estimate any inhibitive or inductive effect of PF-06651600 on the
      pharmacokinetics of midazolam and efavirenz.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Actual">February 21, 2019</completion_date>
  <primary_completion_date type="Actual">January 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>single dose Area under the curve at last quantifiable infinity time of midazolam</measure>
    <time_frame>Hour 0, 0,5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose Area under the Curve from time 0 to 72 hours post-dose of efavirenz</measure>
    <time_frame>hour 0, 0,5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of subjects with significant change from baseline in vital signs</measure>
    <time_frame>hour 0 on study days 1, 4, 10 and 13 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with significant change from baseline in laboratory safety tests results</measure>
    <time_frame>study days -1, 4, 13 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with treatment emergent adverse events (TEAE)</measure>
    <time_frame>Baseline up to 35 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>midazolam/efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06651600/midazolam/efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600</intervention_name>
    <description>200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days</description>
    <arm_group_label>PF-06651600/midazolam/efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>single administration of midazolam 2 mg oral solution</description>
    <arm_group_label>PF-06651600/midazolam/efavirenz</arm_group_label>
    <arm_group_label>midazolam/efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>single administration of efavirenz 50 mg capsule</description>
    <arm_group_label>PF-06651600/midazolam/efavirenz</arm_group_label>
    <arm_group_label>midazolam/efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and female participants who are healthy Body mass index (BMI) of 17.5 to 30.5 kg/m2;
        and a total body weight &gt;50 kg

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,
             dermatological, or allergic disease

          -  Any condition possibly affecting drug absorption

          -  Known immunodeficiency.

          -  Infection with hepatitis B or hepatitis C viruses

          -  acute or chronic infections or infection history judged to be clinically significant
             by the investigator

          -  History of any lymphoproliferative disorder

          -  known present or a history of malignancy other than a successfully treated or excised
             non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in
             situ.

          -  live (attenuated) vaccines within 6 weeks prior to the first dose of investigational
             product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7981017&amp;StudyName=A+Phase+1%2C+Randomized%2C+Open+Label%2C+2-way+Crossover+Study+To+Estimate+The+Effect+Of+Multiple+Dose+Pf-06651600+On+The+Pharmacokinetics+Of+Single+Dose+Midazolam+And+Efavirenz+In+Healthy+Participants</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

